

## Comment

### Letter to the Editor: Spatial proximity of tumor–immune interactions predicts patient outcome in hepatocellular carcinoma

Gaoyao Peng<sup>1,2</sup> · Jiangfa Li<sup>2</sup> · Xinchou Wang<sup>1,2</sup>

Received: 4 June 2024 / Accepted: 3 December 2024

Published online: 18 December 2024

© The Author(s) 2024 [OPEN](#)

#### Abstract

We read with interest the study entitled "Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular "in *Hepatology* (Maestri E, Kedei N, Khatib S, et al. in *Hepatology* 79(4):768–79, 2024). This study utilized highly multiplexed CODEX imaging to comprehensively analyze the spatial interactions between tumor and immune cells in hepatocellular carcinoma (HCC), yielding several meaningful findings and innovatively proposing the concept of the spatial neighborhood of immune cell infiltration and confirming its association with patient prognosis. After reading the article carefully, we have some suggestions to point out.

#### To the editor:

We read with interest the study entitled "Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular "in *Hepatology* [1]. This study utilized highly multiplexed CODEX imaging to comprehensively analyze the spatial interactions between tumor and immune cells in hepatocellular carcinoma (HCC), yielding several meaningful findings and innovatively proposing the concept of the spatial neighborhood of immune cell infiltration and confirming its association with patient prognosis. This research meticulously quantifies computational imaging and constructs spatial networks (e.g., Voronoi diagrams) to explore cell–cell spatial interactions, particularly the proximity between CD8 + T cells and tumor cells, which has been less explored in previous studies. This method reveals potential communication networks and niches within the TME that are significant for understanding different immunotherapy responses and overall cancer prognosis. Specifically, the proximity between CD8 + T cells and tumor cells emerges as a strong prognostic indicator for patients, providing a new perspective for stratified treatment of liver cancer patients. We completely agree with these valuable and interesting findings. After reading the article carefully, we have some suggestions to point out.

First, the antibody library for CODEX technology is limited, and some markers of interest (such as FOXP3) were not included, limiting the analysis of regulatory T cells and other cell types. In addition, as the authors note, this test requires multiple antibody combinations and may be expensive [2]. Secondly, the study is limited to a single time point of HCC tissue sections, so more examination of the dynamic changes in the tumor microenvironment is needed. Some studies showed that RNA could reflect the dynamic changes in the tumor's immune environment [3]. By detecting pancreatic cancer tissues, Chen K et al. [4] found that there were significant differences in the tumor immune microenvironment of pancreatic cancer in different clinical stages. Compleme-secreting cancer associated fibroblasts (ssCAF) are significantly correlated with the changes in the tumor immune microenvironment, and the level of ssCAF can reflect the changes in the tumor microenvironment. At present, most studies on RNA mainly focus on tumor tissues. Still, in many cases, patients have not undergone surgical resection or

---

✉ Jiangfa Li, 247546160@qq.com; ✉ Xinchou Wang, 984200027@qq.com | <sup>1</sup>Department of Breast Surgery, Guilin Women's and Children's Hospital, No. 20, Fengbei Road, Guilin, China. <sup>2</sup>Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Xiufen District, No. 15, Lequn Road, Guilin 541001, Guangxi, China.



biopsy, and detecting RNA without tissue samples is challenging. If circulating RNA can be detected from peripheral blood to predict tumor immune microenvironment, it will have vital clinical significance. Thirdly, cell segmentation and phenotype annotation still require manual adjustment, which may introduce bias. Deep learning algorithms are expected to improve the accuracy and scalability of this process [5]. Radiomics has a high value in evaluating and predicting the tumor microenvironment [6], and it can be assessed after patient imaging at no additional cost. Radiomics can also detect spatial relationships in the microenvironment between tumor cells and immune cells [7]. More exciting results may appear if the authors further compare or combine radiomics with highly multiplexed CODEX imaging.

Despite these limitations, this study demonstrates the potential of multiplexed imaging spatial analysis in revealing the characteristics of the HCC immune microenvironment and discovering new prognostic biomarkers. Multiplexed image analysis applies to quantitative analysis of pathology specimens in immuno-oncology [8]. That will help develop individualized treatment strategies for different HCC subtypes. Future studies may further explore the dynamic changes of the immune microenvironment during immunotherapy to further improve the clinical prognosis of HCC patients.

**Author contribution** G.Y.P., J.F.L. and X.C.W. wrote the main manuscript text. All authors reviewed the manuscript.

**Funding** None.

**Data availability** “The datasets used and analysed during the current study available from the corresponding author on reasonable request.”

## Declarations

**Ethics statement** Not applicable.

**Competing interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Maestri E, Keddi N, Khatib S, et al. Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma. *Hepatology*. 2024;79(4):768–79.
2. Zhou Z, Jiang Y, Sun Z, et al. Virtual multiplexed immunofluorescence staining from non-antibody-stained fluorescence imaging for gastric cancer prognosis. *EBioMedicine*. 2024;107: 105287.
3. Tan Z, Chen X, Zuo J, et al. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. *J Transl Med*. 2023;21(1):223.
4. Chen K, Wang Q, Li M, et al. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. *EBioMedicine*. 2021;66: 103315.
5. Feng X, Yu Z, Fang H, et al. Plantorganelle Hunter is an effective deep-learning-based method for plant organelle phenotyping in electron microscopy. *Nat Plants*. 2023;9(10):1760–75.
6. Huang W, Jiang Y, Xiong W, et al. Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer. *Nat Commun*. 2022;13(1):5095.
7. Antunes JT, Ismail M, Hossain I, et al. RADlomic Spatial Textural Descriptor (RADISTAT): quantifying spatial organization of imaging heterogeneity associated with tumor response to treatment. *IEEE J Biomed Health Inform*. 2022;26(6):2627–36.
8. Mi H, Ho WJ, Yarchoan M, et al. Multi-scale spatial analysis of the tumor microenvironment reveals features of cabozantinib and nivolumab efficacy in hepatocellular carcinoma. *Front Immunol*. 2022;13: 892250.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.